Pharming Group (PHAR) Q1 2026 earnings review
Joenja Momentum Masks RUCONEST Drag; Steep Climb Required for 2026 Guidance
Total revenue declined 8% YoY to $72.4M, dragged down by a 15% drop in the flagship RUCONEST franchise. Management attributed the weakness to anticipated inventory drawdowns and an international market exit, though U.S. competitive dynamics also played a role. On a positive note, Joenja (leniolisib) revenue surged 34% YoY to $14.1M, driven by steady U.S. patient additions and new international momentum. Despite the revenue contraction, disciplined cost management narrowed the net loss to $5.2M. However, the reaffirmed FY26 revenue guidance of $405-$425M implies a massive acceleration for the remainder of the year, requiring an average quarterly run rate of ~$114M moving forward.
🐂 Bull Case
Joenja revenue grew 34% YoY, supported by a 25% increase in U.S. patients on paid therapy (up to 127). The commercial base is solidifying with approvals in Japan and a positive CHMP opinion in Europe.
Despite top-line pressure, Pharming generated $2.0M in positive operating cash flow, demonstrating financial discipline while still investing $25.5M in R&D to advance the pipeline.
🐻 Bear Case
With only $72.4M booked in Q1, Pharming needs to generate ~$342M over the next three quarters to hit the midpoint of its $405-$425M guidance. This requires a dramatic, unprecedented acceleration in RUCONEST and Joenja sales.
While management cites inventory drawdowns (-8%) and non-U.S. exits (-3%), the remaining -4% of RUCONEST's 15% decline points to competitive headwinds from oral prophylactics in the U.S. HAE market.
⚖️ Verdict: ⚪
Neutral. The pipeline progress and Joenja's growth are commendable, but the math behind the reaffirmed FY26 revenue guidance is highly concerning. The 15% drop in RUCONEST introduces significant execution risk for the rest of the year.
Key Themes
Joenja U.S. Commercial Traction Accelerating
Joenja is establishing itself as a vital growth engine. U.S. patients on paid therapy reached 127 in Q1 2026, marking a 25% increase from Q1 2025. This steady, sequential patient accumulation validates the commercial strategy and prescriber acceptance for APDS.
Global APDS Regulatory Breakthroughs
International expansion is moving from promise to reality. The CHMP adopted a positive opinion for Joenja in the EEA (ages 12+), and Japan granted approval for patients aged 4 and older—the first such pediatric approval globally. These milestones de-risk the ex-U.S. growth trajectory for 2026 and beyond.
Core Profitability Reversing
Underneath the headline net loss improvement, core operational profitability weakened. Adjusting for the $7.8M non-recurring Abliva acquisition expense in Q1 2025, operating profit actually reversed from a positive $0.8M to a $4.9M loss in Q1 2026. This was driven by the revenue shortfall and higher R&D spend for napazimone (KL1333).
RUCONEST Revenue Erosion Outpacing Excuses
RUCONEST revenue fell 15% YoY to $58.4M. Management quantified an 8% hit from U.S. specialty pharmacy inventory drawdowns and a 3% hit from the planned non-U.S. market exit. The unexplained gap highlights the underlying toll of U.S. competitive dynamics, as patients are increasingly exposed to oral therapies, even if management claims strong retention.
Pediatric Label Expansion Spliced After CRL
Following a January Complete Response Letter (CRL) regarding clinical pharmacology and batch testing, Pharming resubmitted the Joenja pediatric sNDA for the two highest doses only (decision expected <6 months). A separate sNDA for the lowest doses will be filed in summer 2026. This fragmented approach delays full market access for the 4-11 year demographic.
Expanding Leniolisib Beyond APDS
Pharming successfully fully enrolled two Phase II trials for leniolisib targeting Primary Immunodeficiencies (PIDs) and Common Variable Immunodeficiency (CVID) with immune dysregulation. With readouts slated for 2H 2026, this represents a major catalyst, targeting a U.S. patient population of >15,000 compared to the ~1,000 global APDS patients.
Other KPIs
Stable. Generated positive net cash flow from operations despite the $4.9M operating loss, an improvement from $0.2M in Q1 2025. This underscores tight working capital management in the face of top-line volatility.
Decelerating. Down from $181.1M at the end of FY25. The $9.3M sequential decrease was primarily driven by a one-time $12.3M settlement for the early termination of the DSP facility lease at Pivot Park in the Netherlands. Balance sheet remains well-capitalized to fund pipeline milestones.
Guidance
Accelerating significantly. Reaffirmed 8% to 13% YoY growth. With Q1 delivering only $72.4M, the company must average ~$114M per quarter for the rest of the year to achieve the $415M midpoint. Management explicitly notes that 'quarterly fluctuations' are expected, relying heavily on a massive back-half ramp.
Accelerating. Implies 6% to 8% growth YoY. Guidance includes a $60M incremental increase in R&D to advance the clinical pipeline, partially offset by $9M in structural G&A cost reductions initiated in October 2025. The company expects existing cash to cover these pre-launch and pipeline costs.
Key Questions
Revenue Guidance Bridge
With only $72.4M in Q1 revenue, the path to the $405M-$425M guidance requires a dramatic acceleration. Can management break down exactly how much of the $342M gap relies on RUCONEST inventory restocking versus new Joenja ex-U.S. launches?
RUCONEST Competitive Erosion
Beyond the 11% impact from inventory drawdowns and market exits, RUCONEST still declined. What specific competitive pressures in the U.S. are driving this, and what is the floor for this franchise as new oral prophylactics gain share?
Joenja Pediatric Formulation Strategy
Why was the strategic decision made to split the Joenja pediatric sNDA into two separate filings following the CRL, and what specific analytical batch testing hurdles remain for the lowest dose formulation?
Napazimone (KL1333) Trial Status
The presentation notes 'completion of enrollment' in the pivotal FALCON study for napazimone is expected in 2026. Can management provide a more specific timeline for this milestone and when investors should expect the data readout?